Table 1.
Characterization of the formulations by potentiometry, laser diffraction, photon correlation spectroscopy, and nanoparticle tracking analysis
| LNC | MTX-LNC | |
|---|---|---|
| Potentiometry | ||
| pH | 5.8±0.2 | 4.8±0.5 |
| Laser diffraction | ||
| D[4.3] (nm) | 172±21 | 175±17 |
| Span | 1.5±0.2 | 1.6±0.2 |
| Photon correlation spectroscopy | ||
| Dh (nm) | 188±14 | 194±6 |
| PDI | 0.07±0.03 | 0.11±0.01 |
| Electrophoretic mobility | ||
| Zeta potential (mV) | −13±1 | −8±1 |
| Nanoparticle tracking analysis | ||
| Mean diameter (nm) | 191±2 | 215±9 |
| D50 (nm) | 181±4 | 203±11 |
| D90 (nm) | 271±11 | 309±10 |
| PND (×1012 particles mL−1) | 4.55±0.80 | 4.64±0.40 |
Note: Data presented as mean ± standard deviation.
Abbreviations: D[4.3], volume-weighted average diameter; D50, median diameter; D90, the diameter at the 90th percentile; Dh, hydrodynamic diameter; LNC, blank lipid-core nanocapsules; MTX-LNC, methotrexate-loaded lipid-core nanocapsules; PDI, polydispersity index; PND, particle number density.